We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New York-based drug discovery company Volastra Therapeutics has signed a deal with Bristol Myers Squibb (BMS) potentially worth up to $1.1 billion to create new medicines for undisclosed targets. Read More
Baxter Pharmaceuticals Solutions’ contract manufacturing facility in Bloomington, Ind., has received a Form 483 for several deficiencies observed during an FDA inspection from Nov. 2 through Nov. 10, 2021. Read More
The FDA won’t weigh in on whether Regenxbio may be granted a patent extension for its adeno-associated virus (AAV) technology used to produce Novartis’ blockbuster spinal muscular atrophy (SMA) therapy Zolgensma (onasemnogene abeparvovec). Read More
Bristol Myers Squibb (BMS) is accusing AstraZeneca of infringing on several patents related to its blockbuster cancer immunotherapy Opdivo (nivolumab). Read More
The FDA has issued a warning letter to Boca Raton, Fla.-based Iotech International for making unsupported claims for its antiseptic mouthwash and iodine-containing hand sanitizers. Read More